Clinical Trial Update: A Study of SGT-003 Gene Therapy in Ambulant Males With Duchenne Muscular Dystrophy (IMPACT DUCHENNE) [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update for SGT-003 gene therapy in ambulant males with Duchenne Muscular Dystrophy; the study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Duchenne Muscular Dystrophy

Drugs mentioned

• SGT-003

Snippet

Sponsor: Solid Biosciences Inc. | Conditions: Duchenne Muscular Dystrophy | Phase 3 | Status: RECRUITING